The development of an electrochemical biosensor for detecting pulmonary embolism and myocardial infarction represents a significant advancement in point-of-care diagnostics for critical cardiovascular conditions. Both conditions pose severe threats to human health, requiring timely diagnosis to prevent mortality and mitigate complications. Traditional diagnostic methods, such as computed tomography pulmonary angiography for PE and electrocardiography or troponin assays for MI, often involve time-consuming procedures, specialized equipment, and hospital-based settings. An electrochemical biosensor offers a promising alternative, providing rapid, sensitive, and portable diagnostics for these life-threatening conditions [1]. The biosensor operates on the principle of electrochemical transduction, which converts a biochemical interaction into a measurable electrical signal. This technology is particularly suitable for medical diagnostics due to its high sensitivity, specificity, and ability to function in compact, portable devices. In this context, the biosensor was designed to detect specific biomarkers associated with PE and MI, namely D-dimer and cardiac troponins, respectively. D-dimer is a fibrin degradation product that is elevated in the bloodstream during thrombotic events, such as those leading to pulmonary embolism. Similarly, cardiac troponins, specifically troponin I and T, are released into the bloodstream following myocardial injury, making them reliable indicators of myocardial infarction
HTML PDFShare this article
Biosensors & Bioelectronics received 6207 citations as per Google Scholar report
